 Albert Moraska
Concepts (162)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Massage | 8 | 2018 | 43 | 2.910 |
Why?
| | Trigger Points | 5 | 2023 | 13 | 2.550 |
Why?
| | Tension-Type Headache | 4 | 2018 | 7 | 1.860 |
Why?
| | Myofascial Pain Syndromes | 3 | 2023 | 11 | 1.820 |
Why?
| | Lactic Acid | 3 | 2018 | 294 | 0.910 |
Why?
| | Headache Disorders | 1 | 2018 | 14 | 0.610 |
Why?
| | Regional Blood Flow | 1 | 2018 | 457 | 0.520 |
Why?
| | Pain Threshold | 4 | 2018 | 71 | 0.500 |
Why?
| | Glucose | 2 | 2018 | 983 | 0.480 |
Why?
| | Acupressure | 1 | 2012 | 4 | 0.410 |
Why?
| | Pain Measurement | 5 | 2017 | 478 | 0.410 |
Why?
| | Headache | 1 | 2012 | 137 | 0.370 |
Why?
| | Muscle Fatigue | 2 | 2007 | 101 | 0.310 |
Why?
| | Pinch Strength | 1 | 2008 | 1 | 0.300 |
Why?
| | Superficial Back Muscles | 2 | 2018 | 14 | 0.290 |
Why?
| | Carpal Tunnel Syndrome | 1 | 2008 | 26 | 0.290 |
Why?
| | Hand Strength | 1 | 2008 | 111 | 0.280 |
Why?
| | Hand | 1 | 2008 | 153 | 0.260 |
Why?
| | Running | 2 | 2007 | 222 | 0.260 |
Why?
| | Range of Motion, Articular | 1 | 2008 | 360 | 0.250 |
Why?
| | Treatment Outcome | 5 | 2018 | 10110 | 0.250 |
Why?
| | Musculoskeletal Manipulations | 1 | 2005 | 14 | 0.250 |
Why?
| | Low Back Pain | 1 | 2007 | 102 | 0.240 |
Why?
| | Leg | 1 | 2007 | 236 | 0.230 |
Why?
| | Coxsackievirus Infections | 6 | 1993 | 13 | 0.230 |
Why?
| | Muscle, Skeletal | 3 | 2017 | 1619 | 0.230 |
Why?
| | Waiting Lists | 2 | 2017 | 237 | 0.220 |
Why?
| | Physical Conditioning, Animal | 3 | 2002 | 229 | 0.220 |
Why?
| | Physical Fitness | 1 | 2005 | 203 | 0.220 |
Why?
| | Sports Medicine | 1 | 2005 | 108 | 0.220 |
Why?
| | Antibody Formation | 2 | 2002 | 288 | 0.220 |
Why?
| | Stress, Psychological | 2 | 2002 | 1060 | 0.210 |
Why?
| | Physical Exertion | 2 | 2001 | 207 | 0.210 |
Why?
| | Sports | 1 | 2005 | 221 | 0.200 |
Why?
| | Immune Tolerance | 2 | 2001 | 347 | 0.190 |
Why?
| | Rats, Sprague-Dawley | 4 | 2002 | 2258 | 0.190 |
Why?
| | Myocarditis | 5 | 1994 | 98 | 0.190 |
Why?
| | Doxorubicin | 3 | 1993 | 322 | 0.180 |
Why?
| | Enterovirus B, Human | 7 | 1994 | 25 | 0.180 |
Why?
| | Extracellular Fluid | 1 | 2018 | 31 | 0.150 |
Why?
| | Interleukin-1 | 1 | 2002 | 949 | 0.150 |
Why?
| | Occipital Lobe | 1 | 2017 | 24 | 0.140 |
Why?
| | Hemocyanins | 3 | 2002 | 62 | 0.140 |
Why?
| | Adult | 6 | 2018 | 35176 | 0.140 |
Why?
| | Single-Blind Method | 1 | 2017 | 267 | 0.130 |
Why?
| | Male | 16 | 2018 | 62757 | 0.130 |
Why?
| | Adaptation, Physiological | 1 | 2000 | 513 | 0.130 |
Why?
| | Pressure | 1 | 2017 | 236 | 0.130 |
Why?
| | Mice, Inbred BALB C | 7 | 1993 | 1227 | 0.120 |
Why?
| | Isometric Contraction | 1 | 2017 | 187 | 0.120 |
Why?
| | Pilot Projects | 2 | 2012 | 1559 | 0.120 |
Why?
| | Humans | 11 | 2023 | 128019 | 0.110 |
Why?
| | Medical Records | 1 | 2015 | 170 | 0.110 |
Why?
| | Heat-Shock Proteins | 3 | 2002 | 133 | 0.110 |
Why?
| | Myocardium | 5 | 2002 | 967 | 0.110 |
Why?
| | Microdialysis | 1 | 2012 | 51 | 0.100 |
Why?
| | Female | 7 | 2018 | 68016 | 0.100 |
Why?
| | T-Lymphocytes | 4 | 1993 | 1921 | 0.100 |
Why?
| | Lactates | 1 | 2012 | 83 | 0.100 |
Why?
| | Depression | 1 | 2001 | 1290 | 0.100 |
Why?
| | T-Lymphocytes, Cytotoxic | 2 | 1992 | 168 | 0.100 |
Why?
| | Young Adult | 2 | 2018 | 12281 | 0.090 |
Why?
| | Immunity | 1 | 1992 | 132 | 0.090 |
Why?
| | Rats | 5 | 2002 | 5199 | 0.090 |
Why?
| | Self Report | 1 | 2015 | 796 | 0.090 |
Why?
| | Antibodies | 1 | 1992 | 392 | 0.080 |
Why?
| | Autoimmune Diseases | 1 | 1993 | 423 | 0.080 |
Why?
| | Immunoglobulin M | 2 | 2001 | 272 | 0.080 |
Why?
| | Pain Management | 1 | 2012 | 317 | 0.080 |
Why?
| | Middle Aged | 3 | 2018 | 30812 | 0.070 |
Why?
| | Research | 1 | 2011 | 408 | 0.070 |
Why?
| | Immunoglobulin G | 2 | 2002 | 842 | 0.070 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 3 | 2002 | 815 | 0.070 |
Why?
| | Motor Activity | 2 | 2002 | 667 | 0.060 |
Why?
| | Heart | 4 | 1992 | 637 | 0.060 |
Why?
| | Adrenal Glands | 2 | 2002 | 70 | 0.060 |
Why?
| | Animals | 13 | 2002 | 34487 | 0.050 |
Why?
| | Cells, Cultured | 4 | 2002 | 4006 | 0.050 |
Why?
| | Citrate (si)-Synthase | 2 | 2000 | 58 | 0.050 |
Why?
| | Quality of Life | 1 | 2015 | 2672 | 0.050 |
Why?
| | Relaxation Therapy | 1 | 2002 | 17 | 0.050 |
Why?
| | Body Weight | 3 | 2002 | 930 | 0.050 |
Why?
| | Amitriptyline | 1 | 2002 | 19 | 0.050 |
Why?
| | Electroshock | 1 | 2002 | 143 | 0.050 |
Why?
| | Lymphocytes | 2 | 2002 | 367 | 0.050 |
Why?
| | Antigens, Viral | 2 | 1993 | 174 | 0.050 |
Why?
| | Immune System | 1 | 2002 | 176 | 0.050 |
Why?
| | Transcortin | 1 | 2000 | 16 | 0.040 |
Why?
| | Electric Stimulation | 1 | 2001 | 268 | 0.040 |
Why?
| | Nitrites | 1 | 2000 | 81 | 0.040 |
Why?
| | Immunity, Cellular | 1 | 2002 | 263 | 0.040 |
Why?
| | Adjuvants, Immunologic | 1 | 2001 | 221 | 0.040 |
Why?
| | Exercise | 1 | 2011 | 1917 | 0.040 |
Why?
| | Up-Regulation | 1 | 2002 | 822 | 0.040 |
Why?
| | Thymus Gland | 1 | 2000 | 309 | 0.040 |
Why?
| | Stress, Physiological | 1 | 2002 | 411 | 0.040 |
Why?
| | Adolescent | 1 | 2018 | 20158 | 0.040 |
Why?
| | Reference Values | 1 | 2000 | 776 | 0.040 |
Why?
| | Lipopolysaccharides | 1 | 2002 | 854 | 0.040 |
Why?
| | Lymphocyte Activation | 2 | 2000 | 1096 | 0.040 |
Why?
| | Spleen | 3 | 2002 | 507 | 0.040 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2002 | 1943 | 0.040 |
Why?
| | Clinical Trials as Topic | 1 | 2002 | 997 | 0.040 |
Why?
| | Streptococcus pyogenes | 2 | 1994 | 32 | 0.030 |
Why?
| | Weight Gain | 1 | 2000 | 503 | 0.030 |
Why?
| | Colorado | 1 | 2007 | 4369 | 0.030 |
Why?
| | Chronic Disease | 1 | 2002 | 1690 | 0.030 |
Why?
| | Cross Reactions | 2 | 1993 | 129 | 0.030 |
Why?
| | Research Design | 1 | 2002 | 1034 | 0.030 |
Why?
| | Autoimmunity | 2 | 1993 | 860 | 0.030 |
Why?
| | Incidence | 1 | 2002 | 2614 | 0.030 |
Why?
| | Cytotoxicity, Immunologic | 2 | 1993 | 216 | 0.030 |
Why?
| | Time Factors | 2 | 2002 | 6479 | 0.030 |
Why?
| | Surveys and Questionnaires | 1 | 2007 | 5353 | 0.030 |
Why?
| | Bacterial Outer Membrane Proteins | 1 | 1994 | 58 | 0.030 |
Why?
| | Antigens, Bacterial | 1 | 1994 | 119 | 0.030 |
Why?
| | Mice | 8 | 1994 | 16574 | 0.030 |
Why?
| | Antibodies, Monoclonal | 4 | 1994 | 1354 | 0.030 |
Why?
| | Receptors, Antigen, T-Cell, gamma-delta | 1 | 1992 | 100 | 0.020 |
Why?
| | CD8 Antigens | 1 | 1992 | 76 | 0.020 |
Why?
| | Injections, Intravenous | 1 | 1992 | 197 | 0.020 |
Why?
| | Antibodies, Anti-Idiotypic | 1 | 1991 | 57 | 0.020 |
Why?
| | Fluorescent Antibody Technique | 1 | 1992 | 370 | 0.020 |
Why?
| | Hot Temperature | 1 | 1993 | 359 | 0.020 |
Why?
| | Epitopes | 1 | 1993 | 466 | 0.020 |
Why?
| | Brain | 1 | 2002 | 2615 | 0.020 |
Why?
| | Carrier Proteins | 1 | 1994 | 730 | 0.020 |
Why?
| | T-Lymphocyte Subsets | 1 | 1991 | 409 | 0.020 |
Why?
| | Genetic Variation | 2 | 1991 | 933 | 0.020 |
Why?
| | Killer Cells, Natural | 1 | 1992 | 426 | 0.020 |
Why?
| | Bacterial Proteins | 1 | 1994 | 823 | 0.020 |
Why?
| | Animals, Newborn | 3 | 1992 | 801 | 0.020 |
Why?
| | HSP72 Heat-Shock Proteins | 1 | 2002 | 31 | 0.010 |
Why?
| | Rats, Inbred F344 | 1 | 2002 | 251 | 0.010 |
Why?
| | Corticosterone | 1 | 2002 | 214 | 0.010 |
Why?
| | Lymph Nodes | 1 | 2002 | 465 | 0.010 |
Why?
| | Amino Acid Sequence | 2 | 1994 | 2042 | 0.010 |
Why?
| | Molecular Sequence Data | 2 | 1994 | 2820 | 0.010 |
Why?
| | Electrophoresis, Polyacrylamide Gel | 1 | 1999 | 328 | 0.010 |
Why?
| | Mitochondria, Heart | 1 | 1999 | 92 | 0.010 |
Why?
| | Blotting, Western | 1 | 1999 | 1169 | 0.010 |
Why?
| | Heart Rate | 1 | 1999 | 797 | 0.010 |
Why?
| | Liver | 1 | 2002 | 1826 | 0.010 |
Why?
| | Mice, Inbred Strains | 1 | 1994 | 402 | 0.010 |
Why?
| | Major Histocompatibility Complex | 1 | 1994 | 229 | 0.010 |
Why?
| | Mice, Inbred CBA | 1 | 1993 | 52 | 0.010 |
Why?
| | Freund's Adjuvant | 1 | 1992 | 17 | 0.010 |
Why?
| | Lymphocyte Depletion | 1 | 1992 | 129 | 0.010 |
Why?
| | Virulence | 1 | 1992 | 252 | 0.010 |
Why?
| | Cell Separation | 1 | 1992 | 312 | 0.010 |
Why?
| | CD4 Antigens | 1 | 1991 | 138 | 0.010 |
Why?
| | Cyclophosphamide | 1 | 1991 | 227 | 0.010 |
Why?
| | Uridine | 1 | 1991 | 29 | 0.010 |
Why?
| | Leucine | 1 | 1991 | 108 | 0.010 |
Why?
| | Viral Proteins | 1 | 1993 | 321 | 0.010 |
Why?
| | HeLa Cells | 1 | 1991 | 605 | 0.000 |
Why?
| | Peptides | 1 | 1994 | 910 | 0.000 |
Why?
| | Immunotherapy, Adoptive | 1 | 1991 | 295 | 0.000 |
Why?
| | Virus Replication | 1 | 1991 | 444 | 0.000 |
Why?
| | Kinetics | 1 | 1991 | 1617 | 0.000 |
Why?
| | Antibodies, Viral | 1 | 1991 | 601 | 0.000 |
Why?
| | B-Lymphocytes | 1 | 1991 | 812 | 0.000 |
Why?
|
|
Moraska's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|